Page last updated: 2024-08-23

etoposide and hydroxychloroquine

etoposide has been researched along with hydroxychloroquine in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's2 (33.33)29.6817
2010's2 (33.33)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Bialy-Golan, A; Brenner, S; Gat, A; Golan, H1
Feller, JM; Fraser, MJ; Meng, XW; Ziegler, JB1
Junga, Z; Keith, M; Stitt, R; Tracy, C1
Angelov, D; Cotter, AG; Fay, M; Lambert, JS; McGettrick, P; McGinty, T; O'Kelly, B; Sheehan, G1

Reviews

2 review(s) available for etoposide and hydroxychloroquine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Paraneoplastic subacute cutaneous lupus erythematosus: report of a case associated with cancer of the lung.
    Dermatology (Basel, Switzerland), 1997, Volume: 194, Issue:2

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Dermatologic Agents; Doxorubicin; Etoposide; Female; Humans; Hydroxychloroquine; Lung Neoplasms; Lupus Erythematosus, Cutaneous; Middle Aged; Paraneoplastic Syndromes

1997

Other Studies

4 other study(ies) available for etoposide and hydroxychloroquine

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Caspase-3-dependent and caspase-3-independent pathways leading to chromatin DNA fragmentation in HL-60 cells.
    Apoptosis : an international journal on programmed cell death, 2000, Volume: 5, Issue:1

    Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Apoptosis Regulatory Proteins; Aurintricarboxylic Acid; Caspase 3; Caspase Inhibitors; Caspases; Cell Nucleus; Chromatin; DNA Fragmentation; Etoposide; HL-60 Cells; Humans; Hydroxychloroquine; Oligopeptides; Proteins; Subcellular Fractions

2000
Novel use of rituximab in macrophage activation syndrome secondary to systemic lupus erythematosus.
    BMJ case reports, 2017, Aug-21, Volume: 2017

    Topics: Antineoplastic Agents, Immunological; Antirheumatic Agents; Diagnosis, Differential; Etoposide; Female; Humans; Hydroxychloroquine; Infusions, Intravenous; Lupus Erythematosus, Systemic; Macrophage Activation Syndrome; Rare Diseases; Rituximab; Treatment Outcome; Young Adult

2017
Outcome of a patient with refractory Hodgkin lymphoma on pembrolizumab, infected with SARS-CoV-2.
    British journal of haematology, 2020, Volume: 190, Issue:1

    Topics: Adult; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Betacoronavirus; Bleomycin; Coronavirus Infections; COVID-19; Cyclophosphamide; Cytarabine; Dacarbazine; Doxorubicin; Etoposide; Female; Hodgkin Disease; Humans; Hydroxychloroquine; Idarubicin; Mediastinal Neoplasms; Pandemics; Pneumonia, Viral; Positron-Emission Tomography; Prednisone; Procarbazine; SARS-CoV-2; Treatment Outcome; Vinblastine; Vincristine

2020